PSMA ADC

N/A

Report date: 2024/02/05 13:52:36

Base Information

Drug NamePSMA ADC
Drug Alias NamePSMA-ADC
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-PSMA
TargetsProstate-Specific Membrane AntigenTubulin
Therapy Area/IndicationsProstatic NeoplasmsGliosarcomaGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesProgenics Pharmaceuticals IncPsma Development Company Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProgenics Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsGliosarcomaGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A